HOVON 68 CLL
Protocol amendments
Version: April 14, 2008
A randomized phase III study in previously untreated patients with biological highrisk
CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab
EudraCT nr.: 2005-000309-75
Pełna wersja do pobrania w pliku PDF:
HO68 AM2 listofchanges 031008